Advanced search
Start date

EMU granted in the process 2016/17882-4: multichannel system for Electrophysiology/Optogenetics Plexon

Grant number: 19/08146-0
Support type:Multi-user Equipment Program
Duration: June 01, 2019 - May 31, 2026
Field of knowledge:Health Sciences - Medicine
Principal Investigator:João Pereira Leite
Grantee:João Pereira Leite
Home Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
Co-Principal Investigators:Antonio Carlos dos Santos
Assoc. researchers: Ana Paula Andrade Hamad ; Carlos Gilberto Carlotti Jr ; Daniel Leite Góes Gitaí ; Helio Rubens Machado ; Jaime Eduardo Cecilio Hallak ; Jorge Eduardo Moreira ; Kette Dualibi Ramos Valente ; Maria José da Silva Fernandes ; Rodrigo Neves Romcy Pereira ; Tonicarlo Rodrigues Velasco
Associated research grant:16/17882-4 - Drug-resistant epilepsies: diagnostic challenges, associated comorbidities and new experimental approaches, AP.TEM
As informações de acesso ao Equipamento Multiusuário são de responsabilidade do Pesquisador responsável
EMU web page: Página do Equipamento Multiusuário não informada
Tipo de equipamento:Caracterização de Materiais - Imageamento - Elétrico (eletrocardiograma, eletro-encefalograma)
Fabricante: Fabricante não informado
Modelo: Modelo não informado


Nearly half of the patients with epilepsy have poor seizure control, even after more than a century of advances in pharmacological treatment. For some of these drug-resistant cases, surgery may be the indicated treatment. In these cases, surgical success is directly linked to the correct location of the epileptogenic zone (EZ; i.e., the brain area responsible for seizure generation), and both magnetic resonance imaging (MRI) and electroencephalography (EEG) are crucial for defining the boundaries of the EZ. Hippocampal sclerosis and cortical dysplasia are the most frequent pathologies seen in drug-resistant cases, being detected as changes in volume and signal intensity of the various MRI protocols and typical patterns found in video-EEG examinations. However, even with the use of optimized video-EEG and high-field MRI protocols, a considerable percentage of cases remains without a clearly identifiable EZ. As a result, the complete resection of the EZ is incomplete, leaving a significant number of patients with poor seizure control. This lack of proper seizure control has a high impact on the patient's life quality since, in addition to the seizure's impact per se, uncontrolled seizures lead to significant cognitive deficits and are associated with psychiatric comorbidities such as depression and interictal psychosis. The latest technological advances, such as 7 Tesla MR machines and images constructed by EEG data (electrical source imaging, high-density EEG) are promising for a better definition of the EZ. Moreover, experimental studies in multi unitary electrophysiology and optogenetics contributed to a better understanding of the generation and synchronization of neuronal activity that leads to the seizures and the emergence of associated comorbidities. Recent publications from various centers and our group have shown, in patients with medically resistant epilepsy, different patterns of structural, neurochemistry, and connectivity changes between brain structures associated with cognitive and psychiatric comorbidities. Studies of this nature are essential for the development of future therapeutic approaches to the drug-resistant patients. Thus, the central focus of the present thematic project is the pathologic, cognitive, and behavioral changes associated with drug-resistant epilepsy, with particular attention to cases where the EZ is poorly defined. With this aim, the proposed studies is divided into 3 main project groups, as follows: A) Diagnosis and treatment improvement for drug-resistant patients, especially those with normal MRI; B) A better characterization of structural and functional changes (neuroimaging, neuropathological and molecular approaches) in drug-resistant patients with cognitive and psychiatric comorbidities; C) The development of electrophysiological and optogenetic approaches to a better understanding of the mechanisms underlying seizure onset, behavioral and cognitive changes seen in animal models of drug-resistant epilepsy. (AU)